115 related articles for article (PubMed ID: 2886063)
1. L-dopa challenge and relapse in schizophrenia.
Davidson M; Keefe RS; Mohs RC; Siever LJ; Losonczy MF; Horvath TB; Davis KL
Am J Psychiatry; 1987 Jul; 144(7):934-8. PubMed ID: 2886063
[TBL] [Abstract][Full Text] [Related]
2. Methylphenidate challenge as a predictor of relapse in schizophrenia.
Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical reaction to L-dopa in schizophrenic patients.
Alpert M; Friedhoff AJ; Marcos LR; Diamond F
Am J Psychiatry; 1978 Nov; 135(11):1329-32. PubMed ID: 707630
[TBL] [Abstract][Full Text] [Related]
4. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
Faraone SV; Brown WA; Laughren TP
J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
[TBL] [Abstract][Full Text] [Related]
5. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
Woggon B; Bickel P; Schnyder B
Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
[TBL] [Abstract][Full Text] [Related]
6. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.
Suzuki K; Awata S; Takano T; Ebina Y; Iwasaki H; Matsuoka H
Psychiatry Clin Neurosci; 2005 Aug; 59(4):481-9. PubMed ID: 16048455
[TBL] [Abstract][Full Text] [Related]
7. Reducing the dose of depot neuroleptics in stable schizophrenia.
Dale R; Longdon M; Seeman MV
J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.
Hunt JI; Singh H; Simpson GM
J Clin Psychiatry; 1988 Jul; 49(7):258-61. PubMed ID: 2899071
[TBL] [Abstract][Full Text] [Related]
9. The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo.
Gerlach J; Lühdorf K
Psychopharmacologia; 1975 Oct; 44(1):105-10. PubMed ID: 706
[TBL] [Abstract][Full Text] [Related]
10. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
Viguera AC; Baldessarini RJ; Hegarty JD; van Kammen DP; Tohen M
Arch Gen Psychiatry; 1997 Jan; 54(1):49-55. PubMed ID: 9006400
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of relapse following neuroleptic withdrawal.
Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
[TBL] [Abstract][Full Text] [Related]
12. Ideal and reality of neuroleptic relapse prevention.
Kissling W
Br J Psychiatry Suppl; 1992 Oct; (18):133-9. PubMed ID: 1356363
[No Abstract] [Full Text] [Related]
13. Amphetamine response and relapse risk after depot neuroleptic discontinuation.
Angrist B; Peselow E; Rubinstein M; Wolkin A; Rotrosen J
Psychopharmacology (Berl); 1985; 85(3):277-83. PubMed ID: 2860683
[TBL] [Abstract][Full Text] [Related]
14. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
Steingard S; Allen M; Schooler NR
J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
[TBL] [Abstract][Full Text] [Related]
15. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of schizophrenic patients relapsed on and off medication.
Bartkó G; Mayláth E; Herczeg I
Psychiatry Res; 1987 Nov; 22(3):221-7. PubMed ID: 2893403
[TBL] [Abstract][Full Text] [Related]
17. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
Meltzer HY; Sommers AA; Luchins DJ
J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
[TBL] [Abstract][Full Text] [Related]
18. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
19. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA
Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia.
Lin CH; Chou LS; Lin CH; Hsu CY; Chen CC; Lane HY
J Clin Psychopharmacol; 2012 Dec; 32(6):773-7. PubMed ID: 23131876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
